GSK, Crucell To Test Second-Generation Malaria Vaccine

GlaxoSmithKline and drug company Crucell, a division of Johnson & Johnson, will collaborate with the PATH Malaria Vaccine Initiative to test a second-generation malaria vaccine “within the next couple of months,” Reuters reports. “GSK’s first-generation vaccine, known as RTS,S or Mosquirix, is in late-stage development and could reach the market in 2015. … The new vaccine is an amended version of the current GSK shot that adds an engineered common cold virus developed by Crucell to ‘prime’ the immune system to get a stronger response,” the news service writes (Hirschler, 6/6).